Format

Send to

Choose Destination
Cancer Res. 2013 Sep 1;73(17):5309-14. doi: 10.1158/0008-5472.CAN-13-0444. Epub 2013 Aug 22.

mRNA splicing variants: exploiting modularity to outwit cancer therapy.

Author information

1
Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA. dehm@umn.edu

Abstract

Systemic cancer therapy has traditionally exploited vulnerabilities in cancer cells, a strategy which has become more precise with the identification and targeting of driver oncogenes. However, persistent tumor growth due to primary (de novo) or secondary (acquired) resistance limits therapeutic efficacy for many patients. Alternative splicing is important for increasing the diversity of the cellular proteome, and is a process frequently deregulated during cancer development and progression. In cancer cells, diverse splicing alterations have been identified that eliminate protein domains or enzymatic activities required for efficacy of cancer therapies, promote gain of novel signaling functions that circumvent cancer therapies, and uncouple signaling pathways from upstream regulatory points that are blocked by cancer therapies. The mechanisms underlying these splicing changes range from stable alterations in gene sequence/structure to deregulation of splicing regulatory factors. In this review, the role of splice variants in cancer therapy resistance will be discussed, with examples of how mechanistic understanding of these processes has led to the development of novel strategies for therapy resensitization.

PMID:
23970479
PMCID:
PMC3766449
DOI:
10.1158/0008-5472.CAN-13-0444
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center